Avi B. Markowitz, MD, FACP
Department of General Oncology, Division of Cancer Medicine
About Avi B. Markowitz
Present Title & Affiliation
Primary Appointment
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Galveston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Galveston, TX
Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX
Endowed Position-Bill and Louise Bauer Distinguished Chair in Cancer Research, Department of Cancer Medicine, The University of Texas Medical Branch, Galveston, TX
Education & Training
Degree-Granting Education
| 1981 | University of California School of Medicine, San Francisco, California, US, MD |
| 1977 | Rutgers College New Brunswick, New Brunswick, New Jersey, US, Biochemistry, AB |
Postgraduate Training
| 1984-1986 | Research Fellowship, Cancer Research Institute Fellowship, University of California, San Francisco, California |
| 1981-1984 | Clinical Residency, University of California San Diego, San Diego, California |
| 1978-1979 | Research Fellowship, UCSF School of Medicine, San Francisco, California |
Board Certifications
| 2021 | Internal Medicine - NBPS |
| 2021 | Medical Oncology - NBPS |
| 1991 | Medical Oncology - ABIM |
| 1984 | Internal Medicine - AMIM |
Experience & Service
Academic Appointments
Visiting Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2005 - 2005
Assistant Internist, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1990 - 1995
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1987 - 1995
Assistant Internist, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1987 - 1990
Clinical Instructor, Department of General Oncology, UCSF Cancer Research Institute, San Francisco, CA, 1986 - 1987
Administrative Appointments/Responsibilities
Associate Medical Director, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2009 - 2018
Associate Medical Director, Department of Clinical Cancer Prevention - Research, The University of Texas Medical Branch, Galveston, TX, 2007 - 2009
Clinical Medical Director, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2007 - 2018
Associate Medical Director, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2005 - 2008
Fellowship Program Director, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Galveston, TX, 2005 - 2010
Administrative Director, Department of General Oncology, College Station Medical Center, College Station, TX, 1998 - 2001
Associate Administrative Director, Department of General Internal Medicine - Research, St. Joseph Regional Cancer Center, Bryan, TX, 1995 - 2005
Institutional Committee Activities
Member, UTMB-MD Anderson Medical Oncology Work Group, 2015 - Present
Member, UTMB-Velos Executive Steering Committee, 2013 - Present
Member, Council of Lead Investigators, CTNeT (Statewide Clinical Trials Network of Texas), 2012 - 2013
Member, Board of Directors, Association of Clinical Researchers and Educators, 2009 - Present
Member, Steering Committee, Association of Clinical Researchers and Educators, 2009 - Present
Member, UTMB Cancer Center Day Planning Committee, 2009 - 2009
Member, Southwest Oncology Group Board of Governors, 2008 - 2010
Member, UTMB Pain Medicine Fellowship Multidisciplinary Committee, 2008 - Present
Member, UTMB Quality of Care Committee, 2008 - 2011
Chair, UTMB Cancer Committee, 2008 - Present
Member, UTMB School Cancer Center Membership Committee, 2007 - Present
Member, UTMB Cancer Patient Acceptance Committee, 2006 - Present
Member, UTMB Community Physician Partnerships Committee, 2006 - 2007
Member, Faculty Group Practice Executive Committee, 2006 - 2007
Member, UTMB Faculty Group Practice Executive Committee, 2006 - 2007
Member, UTMB Special Task Force for Interventional Radiology Section in the Department of Radiology and the Department of Medical Management, 2006 - 2007
Member, UTMB Joint Clinical Enterprise Research and Education Committee, 2005 - 2007
Member, UTMB Search Committee for Chairman of Department of Radiology, 2005 - 2007
Member, UTMB Pharmacy & Therapeutics Committee, 2005 - Present
Member, UTMB Cancer Committee, 2005 - Present
Member, Graduate Medical Education Committee, 2005 - 2010
Member, Council of Full Professors, 2005 - Present
Member, CPRIT (Cancer Prevention and Research Institute of Texas)- Clinical Trials Working Group, 2000 - 2012
Board of Directors, University of California, San Francisco Cancer Biotherapy Research Group, 1998 - 2000
Member, St. Joseph Regional Cancer Center Blood Usage Review Committee, 1997 - 2005
Chairman, St. Joseph Regional Cancer Center Pharmacy and Therapeutics Committee, 1997 - 2005
Chairman, College Station Medical Center Cancer Committee, 1997 - 2001
Member, College Station Medical Center Cancer Committee, 1997 - 2005
Cancer Liaison Physician of the Commission on Cancer, University of California, San Francisco American College of Surgeons, 1997 - 2000
Member, Texas Medical Foundation Health Quality Institute, 1995 - Present
Member, St. Joseph Regional Cancer Center Cancer Committee, 1995 - 2005
Member, St. Joseph Regional Cancer Center Pharmacy and Therapeutics Committee, 1995 - 2005
Director, St. Joseph Regional Cancer Center Tumor Conference, 1995 - 2005
Member, University of California San Francisco National Melanoma Faculty, 1995 - 2005
Member, University of California San Francisco Steering Committee, American Cancer Society, Brazos County, 1995 - 2005
Member, University of California San Francisco General Oncology Clinic, 1994 - 2005
Chairman, MD Anderson Cancer Center Clinical Pertinence Subcommittee, 1993 - 1995
Member, MD Anderson Medical Records Committee, 1993 - 1995
Member, MD Anderson Desktop Information Standards Task Force, 1993 - 1995
National Faculty Member, University of California San Francisco Consultant Care Network, 1993 - 1994
Vice-Chairman, MD Anderson Pharmacy and Therapeutics Committee, 1992 - 1995
Member, MD Anderson Database Master Plan Committee, 1992 - 1994
Member, MD Anderson Computer Based Patient Record Steering Committee, 1992 - 1995
Member, MD Anderson Pharmacy and Therapeutics Committee, 1991 - 1995
Expert Panel, University of California San Francisco Cancer Research Institute Grand Rounds (Twice Yearly), 1991 - 2005
Member, MD Anderson Research Medical Library Advisory Committee, 1991 - 1993
Chairman, MD Anderson SMS Computerization Committee, 1990 - 1992
Member, MD Anderson Surveillance Committee, 1990 - 1994
Member, MD Anderson Utilization Committee, 1990 - 1991
Vice-Chairman, MD Anderson Medical Records Committee, 1989 - 1991
Member, MD Anderson Medical Records Committee, 1988 - 1991
Attending Oncologist, University of California San Francisco Biologic Response Modifiers Clinic, 1986 - 1987
Attending Oncologist, University of California San Francisco Gynecologic Oncology Tumor Board, 1986 - 1987
Attending Oncologist, University of California San Francisco Head and Neck Tumor Board, 1986 - 1987
Attending Oncologist, University of California San Francisco General Oncology Clinic, 1986 - 1987
Member, University of California San Francisco Gynecologic Oncology Tumor Board, 1984 - 1987
Member, University of California San Francisco Cancer Research Institute Grand Rounds (Twice Yearly), 1984 - 1987
Member, University of California San Francisco Professional Education Committee, ACS, California Division, 1984 - 1987
Honors & Awards
| Phi Beta Kappa: Rutgers College | |
| President's Undergraduate Fellow: UCSF School of Medicine | |
| Physician of the Year: American Cancer Society, Brazos County | |
| Fellow, American College of Physicians | |
| Best Doctors in America | |
| Best Doctors in Houston | |
| Doctor of Excellence |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Weiser R, Polychronopoulou E, Haque W, Hatch SS, He J, Qiu S, Markowitz A, Gradishar WJ, Kuo YF, Klimberg VS. Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases: An NCDB Analysis. Ann Surg Oncol 28(13):8717-8727, 2021. e-Pub 2021. PMID: 34250555.
- Al Asad O, Salam A, Mannem S, Ninan M, Markowitz A, Jana B. Alternative therapy for Epstein Barr virus related hemophagocytic lymphohistiocytosis. Case Rep Oncol None(None):None, 2015. PMID: None.
- Mesia R, Henke M, Fortin A, Minn H, Ancona ACY, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan ATC, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomized, controlled, open-label phase 2 trial. Lancet Oncology 16(2):208-220, 2015. PMID: None.
- Peguero JA, Khanfar A, Mannem S, Willis M, Markowitz A. Impending carotid blow out syndrome. J Clin Oncol None(None):None, 2014. PMID: None.
- Koshy J, Alperin J, Jana B, Markowitz A, Y-W Q. A case of Philadelphia chromosome positive myeloproliferative neoplasm in a pregnant woman with unusual primary myelofibrosis features. Case Reports in Hematology None(None):None, 2013. PMID: None.
- Ghadimi-Mahani M, McDonnold MA, Jana B, Markowitz A, Willis M, Harirah H. Sarcomatoid carcinoma of the oral cavity during pregnancy. None None(None):None, 2013. PMID: None.
- Abdulla NA, Ninan MJ, Markowitz AB. Rituximab: Current status as therapy for malignant and benign hematologic disorders. BioDrugs 26(2):71-82, 2012. PMID: None.
- Weber MA, Black HR, Fonseca R, Garber J, Gonzalez-Campoy JM, Kimmelstiel C, Markowitz AB, Nakayama D, Stell LK, Stossel TP. Association of clinical researchers and educators :A statement on relationships between physicians and industry. Endocrine Practice 18(6):1029-1037, 2012. PMID: None.
- Gopal M, Abdulla N, Elghetany M, Markowitz A, McClain K. Epstein-Barr virus associated hemophagocytic lymphohistiocytosis: Case report with unusual clinical features with brief review of literature. J Malign Tumours 1(None):60-67, 2011. PMID: None.
- Bhutani MS, Saftiou A, Chaya C, Gupta P, Markowitz AB, Willis M, Kessel I, Sharma G, Zwischenberger JB. Irregular echogenic foci representing coagulation necrosis: a useful but perhaps under-recognized EUS echo feature of malignant lymph node invasion. J Gastrointestin Liver Dis 18(2):181-184, 2009. PMID: None.
- Wang J, Yong FK, Freeman J, Markowitz AB, Goodwin JS. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected non small cell lung cancer. Cancer 112(2):382-390, 2008. PMID: None.
- Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol:4355-4356, 2008. PMID: None.
- Reddy NK, Markowitz AB, Abbruzzese JL, Bhutani MS. Knowledge of indications and utilization of EUS: a survey of oncologists in the USA. J Clin Gastroenterol:892-896, 2008. PMID: None.
- Rao N, Sanguineti G, Chaljub G, Newlands S, Markowitz A, Pena J. Neck levels that are negative on initial CT do not need to be dissected. International Journal of Radiation Oncology Biology Physics None(None):None, 2006. PMID: None.
- Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20(None):937-940, 2002. PMID: None.
- Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O’Brien S, Markowitz A, Kantarjian H. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35 35(None):109-18, 1999. PMID: None.
- Khuri FR, Fossella FV, Lee JS, Murphy WK, Shin DM, Markowitz AB, Glisson BS. Phase II trial of recombinant interferon alfa-2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon and Cytokine Res 18:241-45, 1998. PMID: None.
- Patt YZ, Jones DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14(None):2311-2315, 1996. PMID: None.
- Jones DV, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol None(14):2306-2310, 1996. PMID: None.
- Jones DV, Sugarman SM, Markowitz AB, Levin B, Abbruzzese JL, Evans DB, Charnsangavej C, Smith R, Patt YZ. Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. Oncology Reports 2:1121-1123, 1995. PMID: None.
- Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol 18(None):436-438, 1995. PMID: None.
- Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese J, Bready B, Levin B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296-2300, 1994. PMID: None.
- Kurzrock R, Cohen PR, Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors: A case report and review of the literature. Arch Int Med 154(None):334-340, 1994. PMID: None.
- Kirk IR, Carrasco CH, Lawrence DD, Chuang VP, Richli WR, Charnsangavej C, Kavanagh JJ, Kudelka AP, Freedman RS, Markowitz AB. Intraperitoneal catheters: Percutaneous placement with fluoroscopic guidance. JVIR:299-304, 1993. PMID: None.
- Danhauser LL, Freimann JH, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz AB. Phase I and plasma pharmacokinetic study of infusional 5-fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol:751-761, 1993. PMID: None.
- Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukemoid reaction in advanced transitional cell carcinoma. J Int Med 234(None):417-420, 1993. PMID: None.
- Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. Leukemia 7:214-220, 1993. PMID: None.
- Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. Brit J Urol None(None):388-391, 1993. PMID: None.
- Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs 11:67-69, 1993. PMID: None.
- Sella, Swanson DA, Ro JY, Putnam JB, Amato RJ, Markowitz AB, Logothetis CJ. Surgery following response to interferon--based therapy for residual renal cell carcinoma. J Urol 149(None):19-22, 1993. PMID: None.
- Schilling P, Murray JL, Markowitz AB. Novel tumor necrosis factor toxic effects: Pulmonary hemorrhage and severe hepatic dysfunction. Cancer 69:256-60, 1992. PMID: None.
- Itoh K, Balch CM, Murray JL, Parkinson DR, Markowitz AB, Talpaz M, Lee K, Zukiwski AA, Ross MI, Legha SS, Hayakawa K, Salmeron MA, Augustus LB. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. Vivo 5:647-654, 1991. PMID: None.
- Freimann JH, Markowitz AB. Cytokines and chemotherapy: A new approach to therapy for solid tumors. Cancer Bull:224-232, 1991. PMID: None.
- Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K. Immunological study of interleukin-2 activated tumor-infiltrating lymphocytes for adoptive cellular therapy for human metastatic melanoma and renal cell carcinoma. J Immunother 10(None):None, 1991. PMID: None.
- Neefe JR, Legha SS, Markowitz A, Salmon S, Meyskens F, Groopman J, Campion M, Evans L. Phase II study of recombinant - interferon in malignant melanoma. Am J Clin Oncol 13(None):None, 1990. PMID: None.
- Hudson MM, Markowitz AB, Gutterman JU, Knowles RD, Snyder JS, Kleinerman ES. Effect of recombinant human interleukin 4 on human monocyte activity. Cancer Res 50:3154-3158, 1990. PMID: None.
- Parkinson DR, Talpaz M, Lee KH, Legha S, Markowitz AB, Itoh K, Balch CM, Murray JL, Zukiwski AA, Benjamin RS, Gutterman JU. Interleukin-2 alone and in combination with other cytokines in melanoma: The investigational approach at the University of Texas M. D. Anderson Cancer Center. Cancer Treat Rev 16:39-48, 1989. PMID: None.
- Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, Parkinson D, Ciobanu N, Fisher RI, Boldt DH, Doroshow JH, Rayner AA, Hawkins M, Atkins M. A phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma. J Clin Oncol 4:477-485, 1989. PMID: None.
Other Articles
- Nelson BE, Hong A, Okereke I, Markowitz A, Willis M, Muthukumarana PV, Nawgiri R Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung. Diagn Cytopathol 49(10):1150-1154, 2021. PMID: 34331523.
Abstracts
- Johnson P, Zatarain JR, Mrazek AA, Hellmich J, Gajjar A, Orihuela E, Sonstein J, Silva HC, Markowitz AB, Szabo C, Hellmich MR, Druzhyna N, Zhao Y, Chao C. Urine thiosulfate level is not a reliable biomarker to diagnose prostate or breast cancers. Proc South Texas Chapter Amer Coll Sur, 2015. PMID: None.
- Giralt J, Fortin A, Mesia R, Minn H, Henke M, Ancona A, Cmelak A, Markowitz A, Hotte S, Singh S, Chan A, Merlan M, Zhang A, Oliner K, VanderWalde A. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Proc Am Soc Clin Oncol None(None):None, 2012. PMID: None.
- Cox JA, Eltorky MA, Wolski MJ, Sturgeon JD, Joyner MM, Markowitz AB, Hatch SS. Pleomorphic lobular breast carcinoma: A review of 35 cases at a single institution. Proc Am Soc Clin Oncol 175(None):None, 2011. PMID: None.
- Katta SF, Malani AK, Rodgers HA, Willis M, Markowitz AB. A phase II study of arsenic trioxide (ATO) in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 28(None):None, 2010. PMID: None.
- Giralt J, Trigo JM, Nuyts S, Ozsahin M, Markowitz AB, Daisne J, Skladowski K, Lonchay C, Holeckova P, Smitt M. A phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): interim pooled safety analysis. European Journal of Cancer Supplements 7(2), 2009. PMID: None.
- Montoya ME, Markowitz AB, Klementich F, Palacio D. Docetaxel and fluid retention: Use of single-dose dexamethasone. Proc Am Soc Clin Oncol 25, 2007. PMID: None.
- Gupta P, Tarcin O, Zwischenberger JB, Chaya C, Willis M, Markowitz AB, Kessel IL, Sharma G, Bhutani M. Utility of JAVA based software for computer-aided EUS differentiation of benign and malignant lymph nodes in lung cancer. Am J Gastroenterol, 2007. PMID: None.
- Patt YZ, Hoque A, Jones D, Markowitz A. Phase II trial of cisplatinum, 5-FU, and leucovorin (PFL) for primary duodenal carcinoma (PDC). Proc Am Soc Clin Oncol 14(None):None, 1995. PMID: None.
- Hoque A, Chase J, Lozano R, Markowitz A, Jones DV, Carrasco H, Roh MS, Curley SA, Patt YZ. Educating patients on hepatic arterial infusion (HAI) as an option for treatment of hepatocellular carcinoma (HCC) and colorectal cancer metastatic to the liver. J Cancer Ed None(None):None, 1995. PMID: None.
- Patt YZ, Jones D, Markowitz A. Phase II trial of 5-FU and alpha-interferon in biliary tract cancers (BT). Proc Am Soc Clin Oncol None(None):None, 1995. PMID: None.
- Abbruzzese JL, Evans D, Gravel D, Markowitz A, Patt Y, Pazdur R. Docetaxel (D), a potentially active agent for patients with pancreatic adenocarcinomas. Proc Am Soc Clin Oncol None(None):None, 1995. PMID: None.
- Sugarman SM, Pazdur R, Brown C, Vosika GJ, Jones DV, Markowitz A, Ajani JA, Bready B, Soo E, Levin B. A phase II trial of Immther for previously untreated patients (pts) with metastatic colorectal cancer (CRC) to the liver. Proc Am Soc Clin Oncol None(13):None, 1994. PMID: None.
- Markowitz A, Thielvoldt D, Patt Y, Sugarman S, Jones D, Pazdur R, Abbruzzese J, Levin B. Prolonged continuous intravenous infusion (CIVI) fluorouracil (5-FU) plus daily subcutaneous (sc) interferon-a2b (IFN) has activity in patients (pts) with colorectal cancer (CRC) who have failed prior 5-FU: results of a phase I-II study. Proc Am Soc Clin Oncol 13(None):None, 1994. PMID: None.
- Jones DV, Jr, Sugarman S, Markowitz A, Levin B, Abbruzzese JL, Patt YZ. A phase I-II study of amiodarone (AM) and doxorubicin (DOX) for patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 13(None):None, 1994. PMID: None.
- Markowitz A, Mavligit G, Thielvoldt D. Phase I study of hepatic arterial infusion (HAI) of interleukin-4 (IL-4). Proc Am Assoc Can Res 35(None):None, 1994. PMID: None.
- Markowitz AB. Interleukin-4 (IL-4) in cancer and bone marrow failure. Cancer Investigation, 1994. PMID: None.
- Pazdur R, Rhodes V, Lassere Y, Bready B, Soo E, Ajani JA, Abbruzzese JL, Sugarman S, Jones D, Markowitz A, Ho D, Levin B. UFT plus leucovorin: a potentially effective oral regimen in colorectal carcinoma. Proc Am Soc Clin Oncol 13(None):None, 1994. PMID: None.
- Glisson BS, Palmer JL, Shin DM, Wester M, Markowitz AB. Phase II trial of interferon alfa (IFN) + etoposide/cisplatin (EP) induction and IFN/Megace (M) maintenance in extensive small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol 12, 1993. PMID: None.
- Markowitz AB, Thielvoldt D. Intracavitary interferon-2b is highly active against malignant effusions. Proc Am Assoc Can Res 34, 1993. PMID: None.
- Glisson BS, Markowitz AB, Mortensen T. Phase II trial of etoposide (E)/cisplatin (P)/interferon alpha (IFN) induction and interferon alpha/megace (M) maintenance in extensive small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol 11(None):None, 1992. PMID: None.
- Markowitz A, Thielvoldt D, Yeomans A, Levin B, Hunter C, Gutterman J. Phase I study of intraperitoneal (IP) interferon- (IFN-) and tumor necrosis factor (TNF) in patients (PTS) with advanced intra-abdominal cancer. Proc Am Soc Clin Oncol 11(None):None, 1992. PMID: None.
- Markowitz A, Thielvoldt D, Yeomans A, Rubenstein E, Escalante C, Freimann J, Hunter C, Gutterman J. A phase I study of patients (PTS) with ascites (A) or pleural effusion (PE). Proc Am Soc Clin Oncol 11(None):None, 1992. PMID: None.
Grant & Contract Support
| Title: | A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Funding Source: | NRG Oncology Group |
| Role: | PI |
| Title: | A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients who Achieve and Sustain MR4.5 after Switching to Nilotinib |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Funding Source: | NRG Oncology Group |
| Role: | Collaborator |
| Title: | A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) |
| Funding Source: | Southwest Oncology Group |
| Role: | Collaborator |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Pharmacyclics |
| Role: | PI |
| Title: | Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices (Reveal) |
| Funding Source: | Incyte |
| Role: | Collaborator |
| Title: | Safety and Efficacy of Nab-Paclitaxel (ABRAXANE®) in Combination with Carboplatin as First Line Treatment in Elderly Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (ABOUND 70+) |
| Funding Source: | Celgene |
| Role: | Collaborator |
| Title: | Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin - Ineligible Participants with Advanced Urothelial Carcinoma: Hoosier Oncology Group GU10-147 |
| Funding Source: | Hoosier Oncology Group |
| Role: | Co-I |
| Title: | The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry |
| Funding Source: | Celgene |
| Role: | Collaborator |
| Title: | A Randomized Phase III of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
| Funding Source: | National Surgical Adjuvant Breast and Bowel Project |
| Role: | PI |
| Title: | EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study |
| Funding Source: | Southwest Oncology Group |
| Role: | PI |
| Title: | A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment |
| Funding Source: | Southwest Oncology Group |
| Role: | Collaborator |
| Title: | Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin as Adjuvant Therapy for Node Positive Her2 Negative Breast Cancer: The ABC Trial |
| Funding Source: | NRG Oncology Group |
| Role: | PI |
| Title: | An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients with Newly Diagnosed FMS-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) who are Eligible for Standard Induction and Consolidation Chemotherapy |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer |
| Funding Source: | NRG Oncology Group |
| Role: | PI |
| Title: | A Phase II, Single arm, Open Label Study of Treatment-free Remission after Achieving Sustained MR4.5 on Nilotinib |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | Connect CLL: The Chronic Lymphocytic Leukemia (CLL) Disease Registry |
| Funding Source: | Celgene |
| Role: | PI |
Patient Reviews
CV information above last modified September 20, 2024